Since its outbreak in late 2019, the COVID-19 pandemic has drawn enormous attention
worldwide as a consequence of being the most disastrous infectious disease in the past …

The SARS-CoV-2 main protease (Mpro) is the drug target of Pfizer's oral drug nirmatrelvir.
The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential …

Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or
Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most …

Summary Background Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-
like cysteine protease (3CL pro) inhibitors which have been approved for the treatment of …

SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the
COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and …

Although no longer a public health emergency of international concern, COVID-19 remains
a persistent and critical health concern. The development of effective antiviral drugs could …

Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main
protease (Mpro) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in …

As the SARS-CoV-2 virus continues to spread and mutate, it remains important to focus not
only on preventing spread through vaccination but also on treating infection with direct …

The COVID-19 pandemic has emphasized the urgency for effective antiviral therapies
against SARS-CoV-2. Targeting the main protease (3CLpro) of the virus has emerged as a …

The appearance of several coronavirus pandemics/epidemics during the last two decades
(SARS-CoV-1 in 2002, MERS-CoV in 2012, and SARS-CoV-2 in 2019) indicates that …